Medable Inc., the leading technology provider for modern clinical trials, today announced that Medable CEO and Co-Founder Michelle Longmire will be presenting a corporate update at the 42nd Annual J.P. Morgan Healthcare Conference in San Francisco. The presentation will take place on Wednesday, January 10, 2024, at 7:30 AM Pacific Time (10:30 AM Eastern Time).
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20240103843146/en/
(Graphic: Business Wire)
About Medable
Medable, a Software as a Service (SaaS) cloud platform, is revolutionizing clinical drug development. Our innovative AI-driven technology is transforming clinical trial evidence data collection, analysis, and application, resulting in increased speed and efficiency to bring life-saving therapies to patients faster. We are accelerating the generation of critical evidence by digitizing and connecting with patients at consumer scale. The flexibility of our technology has powered 300+ clinical trials, across 70+ countries, in 115+ languages, with over 1M patients having utilized our platform, ensuring broader, more diverse patient engagement. Medable is trusted by 14 of the top 20 pharmaceutical companies and 9 of the top 10 CROs. To date, we have secured $500M+ in funding from top-tier investors, including Blackstone, Sapphire, PPD/ThermoFisher, and GSR Ventures.
View source version on businesswire.com: https://www.businesswire.com/news/home/20240103843146/en/
Contacts
Nora Volger, SVP Marketing, Medable
Nora.Volger@medable.com / media@medable.com
Burak Over, SVP, Corporate Development & Investor Relations, Medable
Burak@medable.com
If you believe this article contains misleading, harmful, or spam content, please let us know.
Report this article